| ¿µ¹® | insulin | ÇÑ±Û | Àν¶¸° |
|---|---|---|---|
| ¼³¸í | ÀÌÀÚ ¶û°ÖÇѽº¼¶ÀÇ B¼¼Æ÷°¡ ÇÕ¼º-ºÐºñÇϴ ȣ¸£¸ó ´Ü¹éÁú, Æ÷µµ´çÀ» ±Û¸®ÄÚ°ÕÀ¸·Î ¹Ù²Ù´Â È£¸£¸ó´Ü¹éÁú·Î, ºÐÀÚ·®Àº 5,807ÀÌ´Ù. Ç÷ÁßÀÇ ´ç³óµµ »ó½ÂÀ¸·Î ÀÎÇÏ¿© ºÐºñ°¡ ÃËÁøµÈ´Ù. ±ÙÀ°-Áö¹æÁ¶Á÷-°£ µî Ç¥Àû¼¼Æ÷ÀÇ ¼ö¿ëü ´Ü¹éÁú°ú °áÇÕÇÏ¿© Á¤º¸¸¦ ¼¼Æ÷³»·Î Àü´ÞÇÔÀ¸·Î½á Ç÷¾× Áß¿¡¼ ´ç, ÁöÁú, ¾Æ¹Ì³ë»ê ´ë»ç¸¦ Á¶ÀýÇÑ´Ù. ´çÀÇ Á¶Á÷¿¡ ¹Þ¾Æµå¸®´Â °ÍÀ» ÃËÁøÇÏ¿© Ç÷´çÀ» ÀúÇϽÃŲ´Ù. »ý¼º-ºÐºñ·® ÀúÇÏ, Á¶Á÷¼¼Æ÷ÀÇ ¼ö¿ëü ºÎÁ·Àº °íÇ÷´çÀÇ ¿øÀÎÀÌ µÈ´Ù. ¶ÇÇÑ ¾Æ¹Ì³ë»êÀÇ Èí¼ö¿Í ´Ü¹éÁú, Áö¹æÀÇ ÇÕ¼ºÀ» ÃËÁøÇϸç Áö¹æºÐÇØ´Â ¾ïÁ¦ÇÑ´Ù. Àν¶¸°Àº ÀÌÀÚȰ¼º¼ººÐÀÇ ¾àǰÀ¸·Î¼ ´ç´¢º´ ¹× ±âŸ ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù. Àν¶¸°À̶ó´Â ¸íĪÀº ¼¶À̶õ ¶æÀÇ ¶óƾ¾îÀÎ insula¿¡¼ ¿¬À¯ÇÑ´Ù. 1921³â ij³ª´ÙÀÇ ÀÇ»ç F.G. ¹êÆÃ°ú C.H. º£½ºÆ®¿¡ ÀÇÇÏ¿© óÀ½À¸·Î ÀÌÀÚ¿¡¼ äÃëµÇ¾ú°í, ±× ÈÄ Àν¶¸°ÀÇ °áÁ¤À» ¾ò°Ô µÇ¾ú´Ù. F. »ý°Å¿¡ ÀÇÇØ¼ ¼ÒÀÇ Àν¶¸°ÀÇ ±¸Á¶°¡ ¹àÇôÁ³´Âµ¥(1955), À̰ÍÀº ´Ü¹éÁú Áß¿¡¼´Â ÃÖÃÊ·Î ±¸Á¶½ÄÀÌ ¹àÇôÁø °ÍÀÌ´Ù. Æ÷µµ´çÀ¸·ÎºÎÅÍ ±Û¸®ÄÚ°ÕÀÇ »ý¼º, Æ÷µµ´çÀÇ »êÈ ¹× Áö¹æÀ¸·ÎÀÇ ÀüÈ µîÀ» ÃËÁøÇÏ´Â ÀÛ¿ëÀÌ ÀÖ´Ù. µû¶ó¼ Àν¶¸°ÀÇ ¼ö¿ë¾×À» ÁÖ»çÇϸé Ç÷´çÀÌ ÀúÇÏÇϹǷΠ´ç´¢º´ÀÇ Ä¡·á¿¡ ¾²ÀδÙ. ¶Ç Àν¶¸°À» ÇÇÇÏ¿¡ ´ë·® ÁÖ»çÇϸé È¥¼ö¿¡ ºüÁö´Â °ÍÀ» ÀÌ¿ëÇÏ¿© Á¤½Åº´ Ä¡·á¿¡ Àν¶¸°¼îÅ©¿ä¹ýÀ¸·Î¼ ¾²ÀδÙ. |
||
| ¿µ¹® | IDDM(Insulin-Dependent Diabetes Mellitus) | ÇÑ±Û | Àν¶¸°ÀÇÁ¸´ç´¢º´ |
|---|---|---|---|
| ¼³¸í | IDDMÀº ´ç´¢º´ÀÇ Ä¡·á¿¡ ¹Ýµå½Ã Àν¶¸°ÀÌ ÇÊ¿äÇÑ °æ¿ì¸¦ ¸»ÇÑ´Ù. ÁÖ·Î ¿øÀÎÀÌ ÀÌÀÚ¿¡ ÀÖ´Â Àν¶¸°À» ºÐºñÇÏ´Â ¼¼Æ÷ÀÇ ÆÄ±«À̸ç ÀÌ·Î ÀÎÇØ¼ ´ç´¢º´ÀÇ Ä¡·áÁ¦·Î ¾²ÀÌ´Â Àν¶¸°ÀÇ ºÐºñ¸¦ ÃËÁøÇÏ´Â ¾à¹°ÀÌ ÀÌ IDDM¿¡¼´Â ¾²ÀÏ ¼ö°¡ ¾ø°í ¿ÀÁ÷ Àν¶¸°¸¸ÀÌ Ä¡·áÁ¦·Î ¾µ ¼ö°¡ ÀÖ´Ù. ÀüÇüÀûÀÎ Àν¶¸° ÀÇÁ¸Çü ´ç´¢º´Àº ¼Ò¾Æ¿¡¼ ÈçÈ÷ ¹ß»ýÇϰí Àν¶¸° ºÐºñ¼¼Æ÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ Àν¶¸° ºÐºñ´ÉÀº °ÅÀÇ ¾ø´Ù. |
||
| CZI | Crystalline Zinc Insulin |
|---|---|
| CI | cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar... |
| CZI | crystalline zine insulin |
| PZI | Protamine Zinc Insulin |
| IPZ | insulin protamine zinc |
| PZI | protamine zinc insulin |
|---|---|
| Zn | AP)--zinc |
| Cu,Zn-SOD | Copper and zinc containing-superoxide dismutase |
| CuZnSOD | Copper zinc superoxide dismutase |
| Cu,Zn-SOD | Copper-zinc SOD |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| crystalline insulin zinc suspension | A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours. Synonym: crystalline insulin zinc suspension. (05 Mar 2000) |
|---|---|
| amorphous insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| globin zinc insulin | A sterile solution of insulin modified by the addition of zinc chloride and globin; it contains 40 or 80 units per ml; duration of action is about 18 hours. Human insulin, a protein that has the normal structure of insulin produced by the human pancreas, prepared by recombinant DNA techniques and by semisynthetic processes. Immunoreactive insulin (IRI), that portion of insulin in blood measured by immunochemical methods for the hormone; presumed to represent the free (unbound) and biologically active fraction of total blood insulin. Isophane insulin, a modified form of insulin composed of insulin, protamine, and zinc; an intermediately acting preparation used for the treatment of diabetes mellitus. Synonym: NPH insulin. (05 Mar 2000) |
| prompt insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| protamine zinc insulin | Insulin modified by the addition of protamine and zinc chloride; it contains 40 or 80 units per ml. (05 Mar 2000) |
| insulin, protamine zinc | <chemical> A long-acting insulin with an approximate time of onset of 7 hours and duration of action 36 hours, consisting of bovine or pork insulin reacted with zinc chloride and protamine to form a protein complex from which insulin is slowly released. Pharmacological action: hypoglycaemic agents. Chemical name: Insulin protamine zinc (12 Dec 1998) |
| insulin zinc suspension | A sterile buffered suspension with zinc chloride, containing 40 or 80 units per ml; the solid phase of the suspension consists of a mixture of 7 parts of crystalline insulin and 3 parts of amorphous insulin. Synonym: lente insulin. (05 Mar 2000) |
| extended insulin zinc suspension | A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours. Synonym: crystalline insulin zinc suspension. (05 Mar 2000) |
| buffered crystalline penicillin G | Crystalline potassium penicillin G or crystalline sodium penicillin G buffered with not less than 4% and not more than 5% of sodium citrate. (05 Mar 2000) |
| poorly crystalline hydroxyapatite | amorphous hydroxyapatite |
| crystalline | 1. Clear; transparent. 2. Relating to a crystal or crystals. (05 Mar 2000) |
| crystalline capsule | The capsule enclosing the lens of the eye. Synonym: capsula lentis, crystalline capsule, lenticular capsule, phacocyst. (05 Mar 2000) |
| crystalline cataract | A hereditary cataract with a coralliform or needle-shaped accumulation of crystals in the axial region of an otherwise clear lens. (05 Mar 2000) |
| crystalline digitalin | <chemical> A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. Pharmacological action: anti-arrhythmia agents, cardiotonic agent, enzyme inhibitors. Chemical name: Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (12 Dec 1998) |
| crystalline interface | In dentistry, a boundary between adjacent crystals. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|